Compare ICHR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | ELVN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2016 | 2020 |
| Metric | ICHR | ELVN |
|---|---|---|
| Price | $46.61 | $39.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $45.67 | $43.40 |
| AVG Volume (30 Days) | 593.7K | ★ 1.3M |
| Earning Date | 05-04-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $947,652,000.00 | N/A |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $15.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $13.15 | $13.30 |
| 52 Week High | $55.00 | $40.62 |
| Indicator | ICHR | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 71.13 |
| Support Level | $15.74 | $18.04 |
| Resistance Level | $55.00 | N/A |
| Average True Range (ATR) | 3.72 | 2.58 |
| MACD | -0.59 | 0.94 |
| Stochastic Oscillator | 44.82 | 88.04 |
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.